Cleo Diagnostics Current Assets

What does Cleo Diagnostics do? Cleo Diagnostics Ltd develops non-invasive blood-based IVD tests for ovarian cancer detection. The company's three-phased strategy includes the Triage Test for pre-surgical assessment of ovarian masses, the Recurrence Test for post-surgical monitoring of cancer recurrence, and the Screening Test for early detection in asymptomatic women. The CLEO Test Kit detects the protein biomarker CXCL10 in blood samples. These products target healthcare providers, oncologists, and diagnostic laboratories seeking advanced tools for ovarian cancer management. The company generates revenue through the sale of these diagnostic tests and kits to medical institutions and laboratories in Australia and potentially international markets. The Triage Test helps determine malignancy before oncologist referral, the Recurrence Test identifies cancer recurrence after surgery and chemotherapy, and the Screening Test enables early detection in symptom-free women. Cleo Diagnostics Ltd focuses on delivering these specialized tests to address unmet needs in ovarian cancer diagnostics. Revenue streams are derived from the commercialization of these three test phases and the CLEO Test Kit, targeting medical professionals and healthcare facilities requiring accurate and non-invasive diagnostic solutions. Cleo Diagnostics is one of the most popular companies on Eulerpool.